News

AFT Orphan Pharmaceuticals judgment

AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.

Read More

Retirement of Jon Lamb

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb has announced his intention to retire as a director of the company, following the recruitment and appointment of a replacement independent director to the Board. Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service […]

Read More

AFT Pharmaceuticals 2023 Annual Meeting

Annual Meeting Overview

Read More

Notice of Annual Meeting of Shareholders 2023

June 30th 2023 Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand, on Friday, 4 August 2023 commencing at 10.30am (New Zealand time). Agenda A) Addresses Our Chairman, David Flacks, and […]

Read More

Financial Results 2023: AFT declares maiden dividend; record revenue

Financial Results for the 12 Months to 31st of March 2023

Read More

AFT Pharmaceuticals to announce full year results on Monday May 22 2023

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Monday May 22 2023 its full year results for the year ended March 31 2023.

Read More

US FDA sets PDUFA date for Maxigesic IV®

AFT Pharmaceuticals today announces the US Food and Drug Administration has set 17 October 2023 as the date by which it expects to respond to AFT’s application to register Maxigesic IV in the US.

Read More

AFT submits Maxigesic IV® packaging data to the US FDA

AFT Pharmaceuticals announces it has submitted to the US Food and Drug Administration (FDA) data the regulator requested, as it considers registration of the company’s patented intravenous pain relief medicine Maxigesic IV.

Read More

AFT gains first product registration in China for Crystawash Extend and extends Maxigesic IV licensing

As a result of these launches and recent sales AFT will enter the new financial year with Maxigesic sold in 61 countries in various dose forms, 15 more than where we were in March 2022.

Read More

Maxigesic Rapid® tablets gain US FDA approval

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces the US Food and Drug Administration has approved a rapid release tablet form of Maxigesic for the management of mild to moderate acute pain in the US.

Read More

AFT to develop antibiotic eye drop

AFT Pharmaceuticals to develop antibiotic eye drop

Read More

2023 New Year letter to investors

AFT Pharmaceuticals releases New Year letter to shareholders.

Read More